A smaller proportion of the participants in the liraglutide group compared with the placebo group who completed treatment at week 52 required insulin rescue (addition of basal insulin, alone or in combination with bolus insulin, to treat hyperglycaemia). The gene discussed is INS; the disease is Hyperglycemia.